Fig. 2From: Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agentsAPRI and FIB-4 values at different time points in patients with (n = 204) and without (n = 184) thrombocytopenia who achieved SVR12. APRI (a). FIB-4 (b). APRI, AST/platelet ratio index; SVR12, sustained virologic response at 12 weeks after therapy; BA, baseline; 2 W, week 2; 4 W, week 4; EOT, end of therapy; PW12, 12 weeks after direct-acting antiviral therapy. All comparisons are made with baseline levels. ***P < 0.001Back to article page